Spoločnosť JBS Science so sídlom v Pensylvánii dnes oznámila, že získala cenu 3 milióny USD za výskum inovácií v malých podnikoch IIB od National Cancer Institute. Spoločnosť vyvinula prvý tekutý bioptický produkt, ktorým je skríning DNA v moči na včasnú rakovinu pečeňových buniek (HCC).
Despite the monitoring plan for high-risk groups (such as patients with chronic hepatitis, cirrhosis, and fatty liver disease), HCC is usually only discovered at an advanced stage. But if HCC can be detected early, the survival rate can be as high as 40%. Although the detection of the biomarker serum alpha-fetoprotein (AFP) currently shows sensitivity, there is still much room for improvement in the early screening of rakovina pečene. The technology developed by JBS to separate cancer-derived DNA in urine, as well as a special PCR detection method, can more accurately and sensitively detect circulating nádor DNA biomarkers for liver cancer. In a blind pre-validation study, the company stated that if serum AFP is added, the sensitivity of the method will increase to 89%.
Spoločnosť JBS uviedla, že spolupracovala s Jamesom Hamiltonom z Johns Hopkins University Medical Center a Hie-Wonom Hannom z Thomas University Hospital na pokroku vo vývoji testu moču na rakovinu pečene.
https://www.genomeweb.com/molecular-diagnostics/jbs-science-awarded-3m-commercialize-liver-cancer-screening-test#.W62TzNczbIU
